Empaveli (pegcetacoplan) can ease disease burden for people with paroxysmal nocturnal hemoglobinuria (PNH), reducing signs of red blood cell destruction, lowering the need for blood transfusions, and improving fatigue and quality of life, according to a review of 12 studies conducted after Empaveli’s approval in 2021. “These findings, based…